Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash & Current Investments (2017 - 2025)

Neuroone Medical Technologies' Cash & Current Investments history spans 7 years, with the latest figure at $3.6 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 213.98% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, up 213.98%, while the annual FY2025 figure was $6.6 million, 350.01% up from the prior year.
  • Cash & Current Investments reached $3.6 million in Q4 2025 per NMTC's latest filing, down from $6.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $16.2 million in Q4 2021 to a low of $1.1 million in Q4 2024.
  • Average Cash & Current Investments over 5 years is $6.4 million, with a median of $5.9 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: plummeted 72.57% in 2024, then skyrocketed 396.28% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $16.2 million in 2021, then tumbled by 52.78% to $7.6 million in 2022, then plummeted by 64.92% to $2.7 million in 2023, then plummeted by 57.69% to $1.1 million in 2024, then soared by 213.98% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Cash & Current Investments are $3.6 million (Q4 2025), $6.6 million (Q3 2025), and $8.0 million (Q2 2025).